With over 20 years of leadership experience in the technology and life sciences sectors, Karl has successfully led complex EPCM projects across EMEA. His expertise in project execution, operational ...

The agency formulated its advice to manufacturers after coordinating with the CDC and Defense Department. An advisory meeting ...

Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell ...

The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a ...

The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

Funded by investors such as Flagship and General Catalyst, the AI startup claims its platform will help scientists speed up ...

Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...